NCT07180264招募中不适用
Trastuzumab Deruxtecan in Patients With Advanced Breast Cancer: a Real-world Study
Wenjin Yin1 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2025年8月28日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 118
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥18 and older
- •Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
排除标准
- •During pregnancy and lactation
研究组 & 干预措施
Trastuzumab deruxtecan
Trastuzumab deruxtecan, recommended dose 5.4mg/kg, every 21 days
干预措施: Trastuzumab deruxtecan (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)
The time from the date of starting trastuzumab deruxtecan to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.
次要结局
- Adverse events(From the date of starting trastuzumab deruxtecan to the end of the treatment (up to approximately 1 year))
研究者
Wenjin Yin
Deputy Chief of Breast Surgery Department
RenJi Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
A ReaL World Study of DS-8201NCT06945224Fudan University300
招募中
1 期
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric CancerStomach NeoplasmNCT06085755Jeeyun Lee61
招募中
2 期
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerMetastatic Breast CancerAdvanced Breast CancerNCT04965766Gustave Roussy, Cancer Campus, Grand Paris139
终止
1 期
Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast CancerBreast CancerNCT00726180University of Michigan Rogel Cancer Center1
招募中
2 期
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain MetastasesBreast Cancer Stage IVNCT05866432Medical University of Vienna20